House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Ophthalmology

Retinal vein occlusions

AAO · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The AAO retinal-vein-occlusion guidance links treatment to the complications threatening vision: macular oedema, retinal ischaemia, neovascularization and glaucoma. Anti-VEGF treatment is the initial approach to oedema, while laser has distinct roles in selected branch-occlusion oedema and neovascular complications. Repeated retinal assessment and coordinated vascular-risk care remain necessary even when oedema improves. This summary preserves the different pathways for branch and central occlusion.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish the occlusion type and threats to vision

  • Assess retinal vein occlusion with a medical history, comprehensive ocular examination and appropriate retinal imaging. Distinguish branch, hemi-central and central occlusion, assess macular oedema and ischaemia, and look for retinal or iris neovascularization. [1]
  • Ask about the site and duration of visual loss, current medicines, smoking and recreational drugs. Review hypertension, diabetes, dyslipidaemia, cardiovascular disease, sleep apnoea and thrombotic history, alongside glaucoma, prior injections and eye surgery. [1]
  • Record visual acuity, pupils and intraocular pressure. Examine the iris carefully for new vessels and perform gonioscopy before dilation, particularly in ischaemic central occlusion, elevated pressure or high neovascularization risk. [1]
  • Examine the posterior pole and peripheral retina after dilation for oedema, ischaemic signs, new vessels and vitreous or preretinal haemorrhage. A peripheral examination is necessary to assess the extent of disease. [1]

Use imaging to guide treatment and surveillance

  • Use OCT to detect and follow macular oedema, subretinal fluid and vitreoretinal-interface changes. Integrate OCT with visual acuity when deciding to repeat injections or change treatment; retinal thickness alone does not always explain visual function. [1]
  • Consider fluorescein angiography to define vascular occlusion, ischaemia, macular perfusion and leakage, or to guide laser treatment of persistent neovascularization. It can distinguish non-leaking collateral vessels from new vessels that leak. [1]
  • Obtain informed consent before angiography and ensure the facility has an emergency plan for adverse reactions. Ask about pregnancy and breastfeeding; in that context, recommend fluorescein angiography only when absolutely necessary. [1]
  • When vitreous haemorrhage or another media opacity prevents retinal visualization, ultrasound can assess the retina’s anatomical status. [1]

Treat oedema with an individualized plan

  • Intravitreal anti-VEGF therapy is first-line treatment for macular oedema associated with branch or central retinal vein occlusion. Corticosteroids are effective alternatives but carry glaucoma and cataract risks; choose treatment with the patient. [1]
  • For branch-occlusion oedema that responds inadequately or fails to respond to anti-VEGF treatment, consider corticosteroids and/or grid laser. This is an alternative after inadequate response, not evidence that routine combination treatment improves outcomes. [1]
  • Do not delay treating branch-occlusion macular oedema. Grid laser can be considered for a perfused macula with oedema and visual acuity of 20/40 or worse, but anti-VEGF treatment is preferred unless contraindicated because its visual benefit is greater. [1]
  • Do not extrapolate branch-occlusion macular laser benefits to central occlusion: the central-vein trial found no value for focal photocoagulation of central-occlusion macular oedema. [1]

Treat new vessels and monitor for glaucoma

  • For branch occlusion with retinal neovascularization, laser the nonperfused retinal area to reduce vitreous-haemorrhage risk. For central occlusion with retinal or iris neovascularization, dense peripheral panretinal photocoagulation is indicated. [1]
  • Anti-VEGF treatment can provide rapid but unsustained benefit for neovascularization and may help complete laser treatment. It is an adjunct in this setting, while peripheral panretinal photocoagulation provides the longer-term treatment approach. [1]
  • At follow-up, reassess symptoms, systemic risk factors, visual acuity, pupils, pressure and retinal findings, using OCT as appropriate. Inspect the undilated iris and angle for early neovascularization as often as monthly for 6 months in central occlusion and after anti-VEGF cessation in ischaemic central occlusion. [1]

Coordinate vascular care and support vision

  • Coordinate management of hypertension, diabetes and lipid levels with primary care, and communicate the risk to the fellow eye. Systemic evaluation should reflect age and history; consider internal-medicine or haematology referral for possible hypercoagulability assessment in patients under 50. [1]
  • Explain that significant visual loss can persist despite treatment. Offer appropriate vision rehabilitation, counselling and social support when vision remains functionally limiting or further treatment is unavailable. [1]

Limitations and use

  • Injection doses, loading schedules, treatment-extension rules and product-specific contraindications are not reproduced. US regulatory product notes do not establish Indian approval or availability.
  • Systemic-testing recommendations are individualized; this guidance does not mandate a universal thrombophilia panel or an anticoagulation regimen.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Retinal vein occlusions

    Selected recommendation material consulted

Preferred Practice Pattern guideline

Publication details

Issuing organisation
AAO
First published
7 February 2025
Resource type
Preferred Practice Pattern guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish the occlusion type and threats to vision
  • Use imaging to guide treatment and surveillance
  • Treat oedema with an individualized plan
  • Treat new vessels and monitor for glaucoma
  • Coordinate vascular care and support vision
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House